Rua Bioscience (NZSE:RUA) Construction In Progress: NZ$0.00 Mil (As of Dec. 2025)


What is Rua Bioscience Construction In Progress?

Rua Bioscience NZSE:RUA Construction In Progress is NZ$0.00 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Rua Bioscience Construction In Progress Historical Data

* Premium members only.

The historical data trend for Rua Bioscience's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rua Bioscience Construction In Progress Chart

Rua Bioscience Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Construction In Progress
0.20 0.01 0.00 0.00 0.00

Rua Bioscience Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Rua Bioscience Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of NZ$0.00 Mil mean?
Rua Bioscience (NZSE:RUA) has a Construction In Progress of NZ$0.00 Mil as of Dec. 2025. Construction in Progress records the amount of construction work that is not complete. View historical data on Rua Bioscience and its competitors.
Is Rua Bioscience's Construction In Progress too high?
Rua Bioscience's current Construction In Progress is NZ$0.00 Mil.
How does Rua Bioscience's Construction In Progress compare to ZTS and UTHR?
Rua Bioscience's Construction In Progress of NZ$0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Drug Manufacturers company?
A good Construction In Progress depends on the Drug Manufacturers industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Rua Bioscience and its competitors. Rua Bioscience's current Construction In Progress is NZ$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rua Bioscience stock overvalued right now?
Rua Bioscience (NZSE:RUA) has a current Construction In Progress of NZ$0.00 Mil. The current Construction In Progress is NZ$0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Rua Bioscience (NZSE:RUA), the current Construction In Progress is NZ$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rua Bioscience Business Description

Address 704 Te Araroa Road, RD3, Ruatoria, NZL, 4083
Rua Bioscience Ltd is a pharmaceutical company engaged in the production of cannabinoid medicines. The company caters to both domestic and international customers. It operates in one segment, being research and development and the sale of pharmaceutical products in Australia, Germany, and New Zealand.